GlassScriptPhysician profile
Lisa E Medwedeff
NPI 1104827799
$11,398.68
in general payments reported to CMS, 2019-2025
64 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $1,334 · 2021: $1,958 · 2022: $1,550 · 2023: $2,203 · 2024: $1,947 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,567 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,566.76 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,702.28 | 2019-2025 | |
| Novo Nordisk INC | $1,006.62 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $789.14 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $665.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $576.65 | 2019-2025 | |
| Esperion Therapeutics, INC. | $569.63 | 2020-2025 | Nexletol |
| Currax Pharmaceuticals LLC | $569.47 | 2019-2025 | Contrave, Onzetra Xsail, Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.76 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $366.59 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Astellas Pharma US INC | $280.53 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $264.19 | 2019-2024 | Trintellix |
| Ibsa Pharma INC. | $256.24 | 2020-2025 | Licart, Tirosint, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $240.60 | 2021-2025 | |
| Exact Sciences Corporation | $236.05 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $216.46 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Medwedeff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.